RELATED CONTENT
Feature | Nuclear Imaging | Dave Fornell
Just when positron emission tomography (PET) appears to be eclipsing single photon emission computed tomography (SPECT) for cardiac imaging, new advances make SPECT more attractive. Both modalities also have suffered setbacks with radiopharmaceutical supply problems in recent years and both modalities have their pros and cons. Looking toward the future, the question of which modality will dominate remains unanswered. PET shows major promise with exciting new tracers, while new SPECT scanner technology introduced at the Society of of Nuclear Medicine and Molecular Imaging (SNMMI) 2013 meeting may herald a rebirth for SPECT with previously unseen image quality enhancements.
July 23, 2013 
Feature | Thijs Spoor
The next generation of positron emission tomography (PET) imaging agents will herald an age when PET will eclipse single photon emission computed tomography (SPECT) as the “go to” modality for molecular imaging. It will do so by enabling personalized medicine through precision diagnostics, the ability to be delivered cost-effectively in a manner with less radiation to patients, by leveraging hardware advances already being commercialized, and by taking advantage of the extra throughput capacity present in the U.S. installed base of PET/CT scanners.
May 14, 2013 
News
August 3, 2012 — FluoroPharma Medical Inc. announced that they have received high-quality images in an investigator-sponsored clinical trial in China where patients with coronary artery disease (CAD) were given BFPET, its imaging agent for measuring cardiovascular blood flow.
August 03, 2012 
News
June 15, 2009 - FluoroPharma Inc. will present phase I data relating to the safety, dosimetry, and pharmacokinetics in human subjects of BFPET, its novel 18-F labeled PET radiotracer for myocardial perfusion imaging, at the Society of Nuclear Medicine 2009 Annual Meeting in Toronto.
June 15, 2009 News
January 26, 2009 - FluoroPharma Inc., a company developing bolecular imaging agents for the Positron Emission Tomography (PET) market, said today that the United States Patent and Trademark Office issued U.S. Patent No. 7,438,891, covering methods of imaging cardiovascular plaque formation using F18 labeled 2-fluorodeoxy-D-glucose (FDG).
January 26, 2009 News
July 24, 2008 - FluoroPharma said it achieved positive phase I test results for BFPET, a novel Fluorine-18 labeled tracer for PET myocardial perfusion imaging.
BFPET is designed to assess the blood flow in the heart (myocardial perfusion), which is a standard test to assess coronary artery disease (CAD), with more than 9 million Americans undergoing the test annually.
July 23, 2008 